Transaction · 0000950170-25-015359

Hollander David

Hollander David, CMO, GTL, reported a transaction classified as return at Revance Therapeutics, Inc. involving 95212.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

returnSEC transaction code DCMO, GTL
RVNCRevance Therapeutics, Inc.
Filing timeFeb 06
Trade dateFeb 06, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

RVNC price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RVNC since 2025-02-06Filed 575 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
return
Code D
Identifier
0000950170-25-015359
Common Stock
Transaction date
Feb 06, 2025
Filed Feb 06, 2025, 08:58 PM · 0d delay
Shares
95.2k sh
Price unknown
Estimated value
—
Computed from shares × price
Holdings after
0 sh
Direct

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
+2score
Filing-only score

+2

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CMO & Global Therapeutics Lead

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"),…

  2. F2

    Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without intere…

Original filing · 0000950170-25-015359
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RVNC